On Monday, the U.S. Department of Justice’s (DOJ) Attorney’s Office for the District of Maryland issued a press release concerning a settlement arrangement involving the repayment of conditional payments with the law firm of Meyers, Rodbell & Rosenbaum, P.A., a firm based out of Maryland. The law firm entered into the settlement agreement to resolve […] Continue
Yesterday, the Centers for Medicare and Medicaid Services (CMS) held a high level overview webinar of changes coming to the Medicare Secondary Payer Recovery Portal (MSPRP), as we recently discussed here on our blog. The webinar addressed the most recent upcoming enhancement, which will allow electronic payments to be submitted directly through the MSPRP. As […] Continue
Earlier this month, the Food and Drug Administration (FDA) approved esketamine nasal spray, which will be marketed by Johnson & Johnson (J&J) under the trade name of Spravato™. Spravato is approved for use in conjunction with an oral antidepressant for treatment-resistant depression. The term “treatment-resistant” refers to those patients who have failed to achieve relief […] Continue
Last week, the Centers for Medicare & Medicaid Services (CMS) announced two upcoming webinars, aimed at addressing payment functionalities within both the Medicare Secondary Payment Recovery Portal (MSPRP) and Commercial Repayment Center Portal. These latest enhancements to the conditional payment recovery process will enable users of the CMS maintained portals to make electronic payments for […] Continue
In late November 2018, the FDA announced that it was granting Fast Track designation to an investigational drug for the treatment of osteoarthritis (OA). The drug, developed by Galapagos, is known by its identifier GLPG1972/S201086. This drug is one to watch, since it has a novel mechanism of action for this therapeutic category. GLPG1972/S201086 is […] Continue